An update on systemic treatment of differentiated and medullary thyroid cancers: What to do after RAI
|
|
- Gervase Carson
- 6 years ago
- Views:
Transcription
1 An update on systemic treatment of differentiated and medullary thyroid cancers: What to do after AI Disclosures: clinical trial support: - Exelixis, BI, Bayer, ECOG, TOG, GSK - Actogenix, Proacta, BMS, NCI, oche regular cash payments and subsidies: Stanford University: salary, tuition plan, retirement A. Dimitrios Colevas, MD Division of Oncology Stanford School of Medicine A. Dimitrios Colevas, MD Division of Oncology Stanford School of Medicine ET activation in DTC: ET/PTC oncogenic rearrangement: 5-30% of spontaneous PTC 60-70% of radiation induced PTC Signaling via AS/ BA/ MEK/ EK Lanzi et al,. Biochemical pharmacology 77(2009)
2 Kinases and TKI s What are they? Kinases are enzymes TKI= tyrosine kinase inhibitor TKIs stop phosphate addition to specific proteins Mostly act at the ATP binding site. New targeted agents in thyroid cancer G V E G P D G B A c K I T L T 3 c M E T T I E2 sorafenib x x x x x sunitinib x x x x x XL 184 ( cabozantinib) x x x x x x vandetanib x x x Lenvatinib (E7080) x x x lenalidomide X* axitinib x x motesanib x x x x pazopanib x x x vemurafenib X E G E T H D A C The IC 50s for inhibition of ET autophosphorylation of each TKI against Wild-Type (WT) ET and ET mutants Inhibitor ET wildtype IC 50 [nm] ET C634 ET V804L ET M918T Axitinib > Motesanib > Sorafenib Sunitinib Vandetanib > XL DP 2490 < DP 3636 <1 < Modified with permission from AW Gramza et al. Abstract poster #5559, ASCO 2010 Prognosis in DTC: PET matters, AI doesn t obbins,. J. et al. J Clin Endocrinol Metab 2006;91:
3 Medullary Thyroid Carcinoma (MTC) Medullary thyroid cancer Comprises 3 5% of all thyroid cancers and occurs in a hereditary (25%) or sporadic (75%) pattern Activating ET mutations occur in ~100% of hereditary MTCs (germline) and in >50% of sporadic MTCs (somatic) MET is commonly overexpressed in MTC, often in association with phosphorylated ET Status of TKIs: ecent phase 2 trials in MTC Drug Target(s) # patients Activity Available? Sunitinib in MTC, Phase 2 J. A. De Souza et al., J Clin Oncol 28:15s, 2010 (suppl; abstr 5504) Sorafenib 1 Sunitinib 5 ET, VEG, BA, PDG, KIT, LT-3 PDG, KIT, VEG, ET, LT3 Hereditary 5 Sporadic 16 One P Durable eduction 50% YES 7? YES Vandetanib 2 ET, VEG, EG Hereditary 30 ECIST P 20% Durable eduction 73% Motesanib 3 Axitinib 4 XL184 6 VEG 1,2,3, KIT, ET VEG 1,2,3, PDG, KIT, ET ET, VEG2, MET, KIT, TIE2 Hereditary 6 Sporadic 76 ECIST P 2% Durable eduction 48% YES NO 11 ECIST P 18% NO 28 ECIST P 29% eduction 93% NO This trial confirms activity in same range as with other relevant TKIs, independent of ET status. All patients in this trial PD in <6 months prior to enrollment. Pre versus post treatment progression as evidence of benefit. efs: 1 J Clin Oncol 28: J Clin Oncol 28: J Clin Oncol 27: J Clin Oncol 26: J Clin Oncol 27:15s, 2009 (suppl; abstr 6056) 6 3
4 % Tumor Change MTC patient responses in a Phase 1 Study of XL184 azelle Kurzrock et al., ASCO 2010 # a * * * * * * * * * * * Tumor shrinkage was observed regardless of ET mutation status. esponses in patients with prior Vandetanib exposure. No activating ET mutations Activating ET mutations ET status unknown Median response duration not met after 17 months median f/u. Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trial (ZETA) Sam Wells et al. J Clin Oncol Jan 10;30(2): Epub 2011 Oct Study design Locally advanced or metastatic MTC (N=331) 195 pts tested for ET, 95% mutant Vandetanib 300 mg/day n=231 2:1 randomization Progression Optional open-label Vandetanib 300 mg/day Placebo n=100 Study objectives Primary endpoint: progression-free survival (PS) Secondary assessments included: Overall survival Time to worsening of pain Safety and tolerability (CTCAE 3.0) ollow for survival J Clin Oncol Jan 10;30(2):
5 PS (primary endpoint) Vandetanib in MTC: Ph 3 PS by ET mutation status 1.0 Hazard ratio <1 favors Vandetanib avors vandetanib avors placebo 0.9 Vandetanib 300 mg Progression-free survival Placebo Hazard ratio = 0.46 ( ); P< Median: not reached (Vandetanib); 19.3 months (placebo) Time (months) Partial responders ECIST J Clin Oncol Jan 10;30(2): V:45% (104) P:13% (13) (12/13 after x- over to V) J Clin Oncol Jan 10;30(2): Overall survival (there was crossover) Living better? G 3: > 7 stools/day rom J Clin Oncol Jan 10;30(2):
6 Cabozantanib (XL184 by Exelixis) EXAM trial P Schöffski et al, ASCO P Schöffski et al, ASCO EXAM trial P Schöffski et al, ASCO P Schöffski et al, ASCO
7 Timeline for a MTC patient Bosnian war Arab spring alive and well! 2 nd recurrence ecurrence - vandetanib st recurrence diagnosed Kim Jong-Il Kim Jong-un MTC 2010 take home message We can shrink tumors and extend PS in MTC with Vandetanib and XL184 Unclear if this is clinically meaningful. Motesanib and XL184 are promising but Sorafenib and Sunitinib are available now. Is ET really the relevant target? Is best in class biochemically predictable? Tianamen square When do these patients need treatment? with permission rom Lori Wirth MD Is XL184 better or inferior to Vandetanib? Will we ever know? Papillary and follicular thyroid cancer Differentiated Thyroid Carcinoma (DTC) incidence doubled in past decade Mortality rise of 33% 1600 deaths in US, 2009 No meaningful benefit from cytotoxic chemotherapy Subsets of note: BA mutant in PTC ET/ PTC fusion in PTC 7
8 Which agent is leading the pack in DTC? Axitinib in thyroid cancer ph 2 Cohen et al. J Clin Oncol 26: Motesanib in thyroid cancer ph 2 Sherman et al. N Engl J Med 2008;359: axitinib Yttrium conj. sorafenib sorafenib thalidomide motesanib IN +Doxo celecoxib vorinostat gefitinib Yes pazopanib <6 months 18/37 (49%) 12 >20 Modified from Bible et al, Vol 11 October 2010 Sorafenib in thyroid cancer ph 2 Gupta- Abramson et al. J Clin Oncol 26: Sorafenib in thyroid cancer ph 2 Kloos et al. J Clin Oncol 27: Efficacy of pazopanib in progressive, radioiodinerefractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Bible et al, Vol 11 October 2010 Pazopanib in DTC: reversal of growth slopes Pasopanib 800 mg daily in 39 patients with PD in less than 6 months OS PS esponses Survival 8
9 Sorafenib in thyroid: educed doses and BA V600E mutant Vandetanib late breaking news 2012: not just for MTC!. Lancet Oncol 2012; 13: P=0.017 for H % dose reduced in first month to 400 mg QD. One patient with PTC, BA V600E mutant had a dramatic P European Journal of Endocrinology Thyroid eb;21(2): But. Sophie Leboulleux et al. Lancet Oncol 2012; 13: And Sophie Leboulleux et al. Lancet Oncol 2012; 13:
10 And AND CT in progress: Phase 3 Trial of Lenvatinib (E7080) in 131I-efractory Differentiated Thyroid Cancer 50% in DTC, 36% in MTC PS endpoint, placebo controlled Must have progression within past year Open March 2011, 360 patients sought One prior TKI allowed ecruitment ongoing CT in progress: Sorafenib Versus Placebo in AI- efractory Differentiated Thyroid Cancer Open October 2009 Sorafenib versus placebo 419 patients, accrual complete Progression in prior 14 months Crossover to sorafenib permitted PS primary endpoint 10
11 Differentiated Thyroid Carcinoma take home messages: There is hope after radioactive iodine. Many TKIs are active. Sorafenib, Sunitinib, Pazopanib, Vandetanib are all available but not DA approved.????survival??? Sorafenib, E7080 studies END What is the target? VEG? Emerging biological targets BA V600E mutant: PLX 4032 trials? ET/ PTC fusion: Worth the investment? MEK inhibitors may convert AI refractory to AI sensitive rom Alan Ho oral presentation ASCO
New Developments in Thyroid Cancer
New Developments in Thyroid Cancer Eric J. Sherman, MD Professor Vice-Chair for Clinical Operations Chief, Division of Head and Neck Surgery Departments of Otolaryngology, Radiation Oncology, and Immunology
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More information2014 Debates and Didactics in Hematology and Oncology New treatments in the management of thyroid cancer
2014 Debates and Didactics in Hematology and Oncology New treatments in the management of thyroid cancer Taofeek K. Owonikoko, MD/PhD Associate Professor Department of Hematology/Medical Oncology Emory
More informationMANAGEMENT OF REFRACTORY THYROID CANCER RAJKUMAR VENKATRAMANI, MD, MS RARE TUMORS PROGRAM TEXAS CHILDREN S HOSPITAL
MANAGEMENT OF REFRACTORY THYROID CANCER RAJKUMAR VENKATRAMANI, MD, MS RARE TUMORS PROGRAM TEXAS CHILDREN S HOSPITAL CONFLICTS OF INTEREST Policies and standards of the Texas Medical Association, the Accreditation
More informationPromising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer. Marcia Brose MD PhD
Promising New Treatments for Metastatic Differentiated and Medullary Thyroid Cancer Marcia Brose MD PhD Department of Otorhinolaryngology: Head and Neck Surgery Department of Medicine, Division of Hematology/Oncology
More informationMANAGEMENT OF THYROID MALIGNANCIES
MANAGEMENT OF THYROID MALIGNANCIES Taofeek K. Owonikoko, MD, PhD Associate Professor Department of Hematology/Medical Oncology Winship Cancer Institute of Emory University Atlanta, GA 1 Disclosures Research
More informationMedullary Thyroid Carcinoma: New Therapies and Trials
Medullary Thyroid Carcinoma: New Therapies and Trials Matthew D. Ringel, MD Ralph W. Kurtz Chair and Professor of Medicine Director, Division of Endocrinology, Diabetes, and Metabolism The Ohio State University
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More information8/20/2017. Disclosures. Systemic Therapy for Thyroid Cancer: Who, When, and Why? Objectives. Thyroid cancer epidemiology
Disclosures Systemic Therapy for Thyroid Cancer: Who, When, and Why? Steven P. Weitzman, MD, FACE, ECNU The University of Texas MD Anderson Cancer Center Department of Endocrine Neoplasia and Hormonal
More informationRadioiodine-refractory DTC
Oncology: Radioiodine-refractory DTC New Developments in Giuseppe COSTANTE, MD, Head, Endocrinology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Targeted Therapies Targeted Treatments
More informationEvolution and Revolution of Radioiodine Refractory Differentiated Thyroid Cancer
Evolution and Revolution of Radioiodine Refractory Differentiated Thyroid Cancer Steven I. Sherman, M.D. Associate Vice Provost, Clinical Research Naguib Samaan Distinguished Professor Chair, Department
More informationHead & Neck/Thyroid. Recall the efficacy of promising investigational checkpoint inhibitors and EGFR inhibitors being evaluated in SCCHN.
Head & Neck/Thyroid C M E I n f o r m a t i o n TARGET AUDIENCE This activity is intended for medical oncologists, hematologyoncology fellows and other healthcare providers involved in the treatment of
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationNew Aspects of Tyrosine Kinase Inhibitors Marcia S. Brose MD PhD Associate Professor
New Aspects of Tyrosine Kinase Inhibitors Marcia S. Brose MD PhD Associate Professor Department of Otorhinolaryngology: Head and Neck Cancer Department of Medicine, Division of Hematology/Oncology Abramson
More informationS4-NEW TREATMENT ALGORITHMS FOR SYSTEMIC THERAPY IN MANAGING AGGRESSIVE THYROID CANCER
S4-NEW TREATMENT ALGORITHMS FOR SYSTEMIC THERAPY IN MANAGING AGGRESSIVE THYROID CANCER Joshua Klopper and Bryan Haugen University of Colorado School of Medicine An important subset of patients with well
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationTyrosine Kinase Inhibition and Thyroid Cancer
Tyrosine Kinase Inhibition and Thyroid Cancer Loren Michel, M.D. Associate Attending Head and Neck Medical Oncology Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College NY, NY Financial
More informationNews Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium. Tuesday, February 13, 2018
News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium Tuesday, February 13, 2018 News Briefing: Highlights from the 2018 Multidisciplinary Head and Neck Cancers Symposium
More information3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women
Thyroid cancer- what s new Thyroid Cancer Changing epidemiology Molecular markers Lymph node dissection Technical advances rhtsh Genetic testing and prophylactic surgery Vandetanib What s new? Jessica
More informationClinical Policy: Lenvatinib (Lenvima) Reference Number: CP.CPA.251 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Lenvima) Reference Number: CP.CPA.251 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationLenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]
Contains AIC Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Multiple Technology Appraisal Background and Clinical Effectiveness Lead team: Femi Oyebode
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationOsimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study
Osimertinib Activity in Patients With Leptomeningeal Disease From Non-Small Cell Lung Cancer: Updated Results From the BLOOM Study Abstract 9002 Yang JC, Kim DW, Kim SW, Cho BC, Lee JS, Ye X, Yin X, Yang
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer. December 2007
Vandetanib (Zactima) for locally advanced or metastatic medullary thyroid cancer December 2007 This technology summary is based on information available at the time of research and a limited literature
More informationCitation for published version (APA): Verbeek, H. (2015). Medullary Thyroid Carcinoma: from diagnosis to treatment [S.l.]: [S.n.]
University of Groningen Medullary Thyroid Carcinoma Verbeek, Hans IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationIl Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali
Il Tumore del Fegato Prospettive Future nel Trattamento dei Tumori Gastrointestinali Lorenza Rimassa Medical Oncology Unit Humanitas Cancer Center Humanitas Research Hospital Rozzano (Milano) Disclosures
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationMultiple Receptor Tyrosine Kinase Inhibitors
PHARMACY POLICY 5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors Effective Date: Nov. 1, 2018 Last Revised: Oct. 9, 2018 Replaces: N/A RELATED MEDICAL POLICIES: 5.01.517 Use of Vascular Endothelial
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
COME HOME Thyroid Cancer pathway development worksheet, v9 April 13, 2015 Required Structured Data: Stage Staging Components Staging Date Histology Quality Measure(s): Staging (clinical or pathologic)
More informationClinical Policy: Sorafenib (Nexavar) Reference Number: CP.PHAR.69 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Nexavar) Reference Number: CP.PHAR.69 Effective Date: 07.01.11 Last Review Date: 05.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy for
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More information2/21/2016. Cancer Precision Medicine: A Primer. Ovarian Cancer Statistics and Standard of Care in 2015 OUTLINE. Background
Cancer Precision Medicine: A Primer Rebecca C. Arend, MD Division of Gyn Oncology OUTLINE Background Where we are Where we have been Where we are going Targeted Therapy in Ovarian Cancer How to Individualized
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationTratamiento adyuvante y neoadyuvante del cáncer renal en Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet.
Tratamiento adyuvante y neoadyuvante del cáncer renal en 2017 Xavier Garcia del Muro Solans Institut Català d Oncologia Hospitalet. Barcelona Pronóstico del CR mediante un sistema integrado en 468 pts
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationDesign considerations for Phase II trials incorporating biomarkers
Design considerations for Phase II trials incorporating biomarkers Sumithra J. Mandrekar Professor of Biostatistics, Mayo Clinic Pre-Meeting Workshop Enhancing the Design and Conduct of Phase II Studies
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationCabozantinib (Cometriq )
Cabozantinib (Cometriq ) Workshop dose escalation EMA 4/5 Dec 2014 Frans Opdam, internist-clinical pharmacologist Clinical assessor, Dutch Medicines Agency Phase 3 Study XL184-301 (EXAM): Design Cabozantinib
More informationEvolution of Systemic Therapy Clinical Trials in VHL
Evolution of Systemic Therapy Clinical Trials in VHL Ramaprasad Srinivasan, M.D., Ph.D. Investigator and Head, Molecular Cancer Section Urologic Oncology Branch Center for Cancer Research National Cancer
More informationWhy was HOPE 205 a Positive After Years of Negative Studies?
Why was HOPE 205 a Positive After Years of Negative Studies? Prof. Dr. med. Viktor Grünwald Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation Why do we pursue combinations?
More informationReview Article Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies
Journal of Thyroid Research Volume 2012, Article ID 847108, 10 pages doi:10.1155/2012/847108 Review Article Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies Enrique Grande, 1 Juan JoséDíez,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sutent) Reference Number: ERX.SPA.77 Effective Date: 03.01.14 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationMedullary Thyroid Cancer. Caroline S. Kim, MD Perelman School of Medicine at the University of Pennsylvania February 13, 2016
Medullary Thyroid Cancer Caroline S. Kim, MD Perelman School of Medicine at the University of Pennsylvania February 13, 2016 I have no disclosures 30 minutes on Medullary Thyroid Cancer (MTC) Classification
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationReview Article New Insight into the Treatment of Advanced Differentiated Thyroid Cancer
Thyroid Research Volume 2012, Article ID 437569, 8 pages doi:10.1155/2012/437569 Review Article New Insight into the Treatment of Advanced Differentiated Thyroid Cancer Arash Safavi, 1 Aparna Vijayasekaran,
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationDCC-2618, a novel pan-kit and PDGFR
DCC-2618, a novel pan-kit and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST) N. Somaiah, A. Razak, M. Gordon, F.
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationRossella Elisei. Department of Endocrinology, University Hospital, Pisa, Italy
Rossella Elisei Department of Endocrinology, University Hospital, Pisa, Italy THYROID CANCER IS RARE TUMOR AND REPRESENTS ONLY 3.8% OF ALL HUMAN TUMORS All human cancer Thyroid cancer MOST FREQUENT CANCER
More informationClinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study
Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study Mimi I. Hu, Matthew Taylor, Lori Wirth, Viola Zhu,
More informationTechnology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516
Cabozantinib for treating medullary thyroid cancer Technology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationObjectives. Novel Therapies for Advanced Thyroid Cancer. Disclosure Elements. Thyroid Cancer in the United States
Novel Therapies for Advanced Thyroid Cancer Marcia Brose MD PhD Department of Otorhinolaryngology: Head and Neck Surgery Department of Medicine, Division of Hematology/Oncology Abramson Comprehensive Cancer
More informationMINERVA MEDICA COPYRIGHT
Q J NUCL MED MOL IMAGING 2009;53:520-5 Targeted therapy in radioiodine refractory thyroid cancer The majority of differentiated thyroid carcinomas (DTCs) of follicular cell origin are cured with adequate
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationSorafenib in metastatic radioactive iodine refractory differentiated thyroid cancer: A pilot study
MOLECULAR AND CLINICAL ONCOLOGY 2: 87-92, 2014 Sorafenib in metastatic radioactive iodine refractory differentiated thyroid cancer: A pilot study YANG LUO 1,2, YUANKAI SHI 1,2, PUYUAN XING 1,2, LIN WANG
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/36317 holds various files of this Leiden University dissertation. Author: Abdulrahman Hareedy, Randa Mostafa Title: Clinical and molecular studies on differentiated
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationReference No: Author(s) Approval date: October committee. September Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) guidelines for Thyroid cancer Dr Fionnuala Houghton Consultant Clinical Oncologist & Dr Lois Mulholland Consultant Clinical Oncologist
More informationBRAF Inhibitors in Metastatic disease. Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia
Inhibitors in Metastatic disease Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia Disclosures Research Support Pfizer & Cellgene Consultant Provectus Mortality from Melanoma
More informationEncouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST)
2017 ESMO Proffered Paper Encouraging activity of novel pan-kit and PDGFRα inhibitor DCC-2618 in patients (pts) with gastrointestinal stromal tumor (GIST) F Janku, A Razak, M Gordon, D Flynn, M Kaufman,
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationThyroid International
Thyroid International 4 2013 Edited by Peter PA Smyth, UCD, Dublin Published by Merck KGaA, Darmstadt, Germany Gothic Church Santa Maria della Spina Targeted Therapies For Thyroid Cancer David Viola and
More informationVandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
Clinical Medicine Insights: Oncology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
More informationOverview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib)
Overview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib) George D. Demetri, M.D. Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Harvard Medical School
More information